Background: Inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are characterized by the presence of eosinophils and neutrophils. However, the mechanisms that mediate the influx of these cells are incompletely understood. Neutrophil products, including neutrophil elastase and antimicrobial peptides such as neutrophil defensins and LL-37, have been demonstrated to display chemotactic activity towards cells from both innate and adaptive immunity. However, chemotactic activity of LL-37 towards eosinophils has not been reported. Therefore, the aim of the present study was to investigate the chemotactic activity of LL-37 for eosinophils and to explore the mechanisms involved in LL-37-mediated attraction of neutrophils and eosinophils. Methods: Neutrophils and eosinophils were obtained from venous blood of healthy donors. Chemotaxis was studied using a modified Boyden chamber technique. Involvement of formyl-peptide receptors (FPRs) was studied using the antagonistic peptide tBoc-MLP. Activation of the mitogen-activated protein kinase (MAPK) ERK1/2 was studied by Western blotting using antibodies directed against phosphorylated ERK1/2. Results: Our results show that LL-37 chemoattracts both eosinophils and neutrophils. The FPR antagonistic peptide tBoc-MLP inhibited LL-37-induced chemotaxis. Whereas the FPR agonist fMLP activated ERK1/2 in neutrophils, LL-37 did not, indicating that fMLP and LL-37 deliver different signals through FPRs. Conclusions: LL-37 displays chemotactic activity for eosinophils and neutrophils, and this activity is mediated via an FPR. These results suggest that LL-37 may play a role in inflammatory lung diseases such as asthma and COPD.

Keywords:
Eosinophils, Neutrophils, Chemotaxis, Antimicrobial peptides, Innate immunity, Lung inflammation
1.
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J et al: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525–528.
2.
Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J et al: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and T cells. J Exp Med 2000;192:1069–1074.
3.
Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004;75:39–48.
4.
Bals R, Wilson JM: Cathelicidins – a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003;60:711–720.
5.
Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS et al: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001;97:3951–3959.
6.
Sorensen OE, Gram L, Johnsen AH, Andersson E, Bangsboll S, Tjabringa GS et al: Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 2003;278:28540–28546.
7.
Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N: The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997;90:2796–2803.
8.
Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L et al: The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96:3086–3093.
9.
Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H et al: The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997;272:15258–15263.
10.
Frohm NM, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999;67:2561–2566.
11.
Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998;95:9541–9546.
12.
Agerberth B, Grunewald J, Castanos-Velez E, Olsson B, Jornvall H, Wigzell H et al: Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999;160:283–290.
13.
Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R: The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238:325–332.
14.
Bals R, Weiner DJ, Meegalla RL, Wilson JM: Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999;103:1113–1117.
15.
Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA et al: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454–457.
16.
Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC: Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995;63:1291–1297.
17.
Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H et al: Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-α by blocking the binding of LPS to CD14+ cells. J Immunol 2001;167:3329–3338.
18.
Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N et al: The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003;171:6690–6696.
19.
Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE: The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002;169:3883–3891.
20.
Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H et al: A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002;106:20–26.
21.
Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC et al: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004;172:1146–1156.
22.
Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T et al: An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111:1665–1672.
23.
Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N et al: The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003;120:379–389.
24.
Elssner A, Duncan M, Gavrilin M, Wewers MD: A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release. J Immunol 2004;172:4987–4994.
25.
Van Wetering S, Mannesse-Lazeroms SP, van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS: Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol 1997;272:L888–L896.
26.
Dent G, Munoz NM, Ruhlmann E, Zhu X, Leff AR, Magnussen H et al: Protein kinase C inhibition enhances platelet-activating factor-induced eicosanoid production in human eosinophils. Am J Respir Cell Mol Biol 1998;18:136–144.
27.
Koenderman L, Kok PT, Hamelink ML, Verhoeven AJ, Bruijnzeel PL: An improved method for the isolation of eosinophilic granulocytes from peripheral blood of normal individuals. J Leukoc Biol 1988;44:79–86.
28.
McCormick BA, Colgan SP, Delp-Archer C, Miller SI, Madara JL: Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J Cell Biol 1993;123:895–907.
29.
Yang D, Chertov O, Oppenheim JJ: Participation of mammalian defensins and cathelicidins in anti- microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 2001;69:691–697.
30.
Yang D, Chen Q, Chertov O, Oppenheim JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9–14.
31.
Chertov O, Ueda H, Xu LL, Tani K, Murphy WJ, Wang JM et al: Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 1997;186:739–747.
32.
Sun R, Iribarren P, Zhang N, Zhou Y, Gong W, Cho EH et al: Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol 2004;173:428–436.
33.
Le Y, Murphy PM, Wang JM: Formyl-peptide receptors revisited. Trends Immunol 2002;23:541–548.
34.
Bowdish DM, Davidson DJ, Speert DP, Hancock RE: The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 Kinase pathways in primary human monocytes. J Immunol 2004;172:3758–3765.
35.
Bae YS, Park JC, He R, Ye RD, Kwak JY, Suh PG et al: Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils. Mol Pharmacol 2003;64:721–730.
36.
Bae YS, Yi HJ, Lee HY, Jo EJ, Kim JI, Lee TG et al: Differential activation of formyl peptide receptor-like 1 by peptide ligands. J Immunol 2003;171:6807–6813.
37.
Schaller-Bals S, Schulze A, Bals R: Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002;165:992–995.
38.
Kim ST, Cha HE, Kim DY, Han GC, Chung YS, Lee YJ et al: Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 2003;123:81–85.
39.
Lysenko ES, Gould J, Bals R, Wilson JM, Weiser JN: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun 2000;68:1664–1671.
40.
Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B et al: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001;7:180–185.
41.
Tsoumakidou M, Tzanakis N, Siafakas NM: Induced sputum in the investigation of airway inflammation of COPD. Respir Med 2003;97:863–871.
42.
Fahy JV, Liu J, Wong H, Boushey HA: Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: a method for studying allergic airway inflammation. J Allergy Clin Immunol 1994;93:1031–1039.
43.
De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ et al: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985;131:373–376.
44.
Fahy JV, Kim KW, Liu J, Boushey HA: Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843–852.
45.
Gibson PG, Norzila MZ, Fakes K, Simpson J, Henry RL: Pattern of airway inflammation and its determinants in children with acute severe asthma. Pediatr Pulmonol 1999;28:261–270.
46.
Zuurbier AE, Liu L, Mul FP, Verhoeven AJ, Knol EF, Roos D: Neutrophils enhance eosinophil migration across monolayers of lung epithelial cells. Clin Exp Allergy 2001;31:444–452.
47.
Lapperre TS, Hiltermann TJN, van Bree L, Sterk PJ, Stolk J, Rabe KF et al: Relation between neutrophil elastase and eosinophil cationic protein in induced sputum following ozone exposure of mild asthmatics. Eur Respir J 2000;16:219S.
48.
Liu H, Lazarus SC, Caughey GH, Fahy JV: Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am J Physiol 1999;276:L28–L34.
49.
Van Wetering S, Mannesse-Lazeroms SP, Ruhlmann E, Rabe KF, Hiemstra PS: Neutrophil serine proteinases induce eosinophilic cationic protein and LTC4 release by human eosinophils. Eur Resp J 2000;16:100S.
50.
Moy JN, Gleich GJ, Thomas LL: Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol 1990;145:2626–2632.
51.
Page SM, Gleich GJ, Roebuck KA, Thomas LL: Stimulation of neutrophil interleukin-8 production by eosinophil granule major basic protein. Am J Respir Cell Mol Biol 1999;21:230–237.
52.
Malm J, Sorensen O, Persson T, Frohm-Nilsson M, Johansson B, Bjartell A et al: The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 2000;68:4297–4302.
53.
Johnson M, Rennard S: Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 120, 258–270. 2001
54.
Eda R, Sugiyama H, Hopp RJ, Okada C, Bewtra AK, Townley RG: Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation. Int Arch Allergy Immunol 1993;102:391–398.
55.
Erjefalt JS, Korsgren M, Malm-Erjefalt M, Conroy DM, Williams TJ, Persson CG: Acute allergic responses induce a prompt luminal entry of airway tissue eosinophils. Am J Respir Cell Mol Biol 2003;29:439–448.
56.
Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback B, Della-Cioppa G et al: The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999;159:79–86.
57.
Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Yamada S et al: Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions. J Leukoc Biol 2000;68:194–200.
58.
Kaneko T, Alvarez R, Ueki IF, Nadel JA: Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell Signal 1995;7:527–534.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.